Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Paediatric neurodegenerative diseases are frequently caused by inborn errors in glycosphingolipid (GSL) catabolism and are collectively termed the glycosphingolipidoses. GSL catabolism occurs in the lysosome and a defect in an enzyme involved in GSL degradation leads to the lysosomal storage of its substrate(s). GSLs are abundantly expressed in the central nervous system (CNS) and the disorders frequently have a progressive neurodegenerative course. Our understanding of pathogenesis in these diseases is incomplete and currently few options exist for therapy. In this review we discuss how mouse models of these disorders are providing insights into pathogenesis and also leading to progress in evaluating experimental therapies.


Journal article


Neuropathol Appl Neurobiol

Publication Date





343 - 357


1-Deoxynojirimycin, Animals, Bone Marrow Transplantation, Chemotherapy, Adjuvant, Disease Models, Animal, G(M2) Ganglioside, Gangliosides, Glucosylceramides, Glucosyltransferases, Glycosphingolipids, Humans, Lysosomal Storage Diseases, Lysosomes, Mice, Models, Biological, Models, Chemical, Morpholines, Sandhoff Disease, Tay-Sachs Disease, Treatment Outcome